Unaudited Financial Results (Standalone and Consolidated) for the Quarter and Half Year Ended September 30, 2026 is attached herewith

345/LG/SE/NOV/2026/GBSL November 14, 2026 To To BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, Bandra Kurla Complex, Dalal Street, Fort, Mumbai – 400 001 Bandra (E), Mumbai – 400 051 Scrip Code : 509079 Scrip Symbol : GUFICBIO Subject: Unaudited Financial Results (Standalone and Consolidated) of the Company for the Quarter and half year ended September 30, 2026 Dear Sir/Madam, Pursuant to Regulation 30 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘SEBI Listing Regulations’), we wish to inform that the Board of Directors of the Company at its meeting held today, i.e. on Saturday, November 14, 2026, inter-alia, considered and approved the Unaudited Financial Results (Standalone and Consolidated) of the Company for the Quarter and Half Year ended September 30, 2026 along with the Limited Review Report thereon in terms of provisions of Regulation 33 of SEBI Listing Regulations. The copy of the same is enclosed herewith as “Annexure – A”. The meeting of the Board of Directors commenced at 5:00 p.m. and concluded at 06:35 p.m. Kindly take the same on your record. Thanking You, Yours truly, For Gufic Biosciences Limited Ami Shah Company Secretary & Compliance Officer Membership No. A39579 Encl.: As above GUFIC BIOSClENCES LIMITED Regel. Office: 37, Kamala Bhavan II, S. Nityanand Road, Andhen (East), Mumbai -400069 (GIN-L24100MH1984PLC033519) Website -www.gufic.com email-corporaterelations@guficbio.com Ph-022 67261000 Fax -022 67261068 (Rs. in Lakhs except EPS) Unaudited Standalone and Consolidated Statement of Financial Results for the Quarter and Half Year Ended September 30, 2026 Standalone Consolidated Quarter Ended Half Year Ended Year ended Quarter Ended Half Year Ended Year ended 1] Sr, Particulars No, 30-Sep-26 30-Jun-26 30-Sep-25 30-Sep-26 30-Sep-25 31-Mar-26 30-Sep-26 30-Jun-26 30-Sep-25 30-Sep-26 30-Sep-25 31-Mar-26 Unaudited Unaudited Unaudited Unaudited Unaudited Audited Unaudited Unaudited Unaudited Unaudited Unaudited Audited 1 Income a Revenue from operations 28,840.15 26,081.80 23,041.80 54,921.95 45,732.95 94,047.53 28,827.30 26,081.80 23,705.45 54,909.10 46,077.70 94,400.66 b Other income 112.47 45.75 209.05 158.22 298.47 258.21 112.47 45.75 211.55 158.22 304.07 265.74 Total Income 28,952,62 26,127,55 23,250.85 55,080.17 46,031.42 94,305.74 28,939.77 26,127.55 23,917.00 55,067.32 46,381.77 94,666.40 2 Expenses a Cost of materials consumed 15,692.36 10,614.20 11,347.16 26,306.56 20,198.74 42,542.32 15,692.36 10,614.20 11,347.16 26,306.56 20,198.74 42,542.32 b Purchase of stock-in-trade 1,459.58 1,403.08 2,568.58 2,862.66 3,995.40 6,473.08 1,459.58 1,403.08 2,568.58 2,862.66 3,995.40 6,471.09 Changes in inventories of finished goods, work-ini)rogress (3,606.86) (517.31) (3,925.32) (4,124.17) (3,673.16) (6,895.39) (3,619.71) (517.31) (3,471.89) (4,137.02) (3,673.16) (6,895.39) c and stock-in-trade d Employee benefits expense 4,542.88 4,180.49 3,745.06 8,723.37 7,344.74 15,168.08 4,542.88 4,180.49 3,745.06 8,723.37 7,344.74 15,168.08 e Finance cost 1,043.96 931.84 958.45 1,975.80 1,881.81 3,661.14 1,043.96 931.84 958.45 1,975.80 1,881.81 3,661.14 f Depreciation and amortisation expense 773.18 770.61 777.29 1,543.79 1,549.18 3,083.24 773.19 770.61 777.30 1,543.80 1,549.19 3,083.26 g Other expenses 5,898.27 5,728.44 5,726.77 11,626.71 11,054.15 21,724.77 5,902.77 5,740.70 5,731.93 11,643.47 11,097.23 21,981.00 Total Expenses 25,803.37 23,111.35 21,197.99 48,914,72 42,350.86 85,757.24 25,795.03 23,123.61 21,656.59 48,918.64 42,393.95 86,011.50 3 Total Profit before exceptional Items and tax (1-2) 3,149.25 3,016.20 2,052.86 6,165.45 3,680.56 8,548.50 3,144.74 3,003.94 2,260.41 6,148.68 3,987.82 8,654.90 4 Exceptional Items 5 Total Profit Before Tax 3,149.25 3,016.20 2,052.86 6,165.45 3,680.56 8,548.50 3,144.74 3,003.94 2,260.41 6,148.68 3,987.82 8,654.90 6 Tax expense Current tax 644.00 608.00 355.00 1,252.00 577.00 1,370.25 644.00 608.00 374.00 1,252.00 596.00 1,370.25 Deferred tax 156.39 162.15 204.15 318.54 402.52 863.38 153.88 164.66 204.15 318.54 402.52 863.38 Short/(Excess) tax provision of earlier years Total Tax Expenses 800.39 770.15 559.15 1,570.54 979.52 2,233.63 797.88 772.66 578.15 1,570.54 998.52 2,233.63 7 Net Profit for the period from continuing operations 2,348.86 2,246.05 1,493.71 4,594.91 2,701.04 6,314.87 2,346.86 2,231.28 1,682.26 4,578.14 2,989.30 6,421.27 Less: Share of Profit/ (Loss) transferred to Minority Interest (0.03) (0.14) (0.03) (0.14) (0.20) 8 Total Profit for period 2,348.86 2,246.05 1,493.71 4,594.91 2,701.04 6,314.87 2,346.89 2,231.28 1,682.40 4,578.17 2,989.44 6,421.47 9 other Comprehensive Income (OCI) a) Items that will not be reclassified to Profit or Loss 66.72 66.72 Less: Income tax relating to items that will not be reclassified (16.79) (16.79) to Profit or Loss b) Items that will be reclassified to Profit or Loss (10.03) 10.03 Less: income tax relating to items that will be reclassified to 2.51 (2.51) Profit or Loss Other Comprehensive Income I Loss (net of taxes) 49.93 (7.52) 7.53 49.93 10 Total Comprehensive Income 2,348.86 2,246.05 1,493.71 4,594.91 2,701.04 6,364.80 2,339.37 2,238.81 1,682.40 4,578.17 2,989.44 6,471.40 11 othe Equity Reserves 65,415.42 65,492.03 12 Details of Equity Share Capital Paid-up equity share capital 1,002.83 1,002.83 1,002.83 1,002.83 1,002.83 1,002.83 1,002.83 1,002.83 1,002.83 1,002.83 1,002.83 1,002.83 Face value of equity share capital (Rs.) 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 13 Earning per equity share . Basic earnings per share from continuing and discontinued 1 ooerations 2.34 2.24 1.49 4.58 2.69 6.30 2.34 2.22 1.68 4.57 2.98 6.40 .. Diluted earnings per share from continuing and discontinued 11 2.34 2.24 1.49 4.58 2.69 6.30 2.34 2.22 1.68 4.57 2.98 6.40 lnnAr~finn~ GUFIC BIOSCIENCES LIMITED Regd. Office: 37, Kamala Shaven 11, S. Nityanand Road, Andheri (East}, Mumbai-400069 (CIN-L24100MH1984PLC033519} Website-www.gufic.com email -corporaterelations@guficbio.com Ph-022 67261000 Fax -022 67261068 (Rs.inLikhs) Unaudited Standalone and Cons dated Statement of Assets and Liab1hties as at Se ember 30, 2026 Standalone Consolidated 2] Particulars Asal As at Asat Asat 30-Se 26 31-Mar-26 30-Se -26 31-Mar-26 (Unaudited) (Audited) (Unaudited) (Audited) ASSETS Non-Current Assets Property, plant and equipment 45,977.45 46,707.32 45,977.60 46,707.32 Intangible assets 589.41 616,19 589.41 616.37 Capital work-in-progress 5,247.66 2,214.46 5,247.66 2,214.46 Right of use assets 1,443.56 1,777.94 1,443.56 1,777.94 Financial Assets i. Investments 978,02 287.09 869.36 178.43 ii. Loans 48,67 52.22 48.67 52.22 iii. Other financial assets 1,141.11 1,141.35 1,141.21 1,142.80 Other non-current assets 1,430.35 1,336.24 1,430.35 1,336.34 Total Non.Current Assets 56,856.23 54,132.81 56,747.82 54,025.88 Current Assets Inventories 37,207.77 32,446.66 37,220.62 32,446.66 Financial Assets i. Trade receivables 32,613.49 'lf,,7'.Jd.67 32,597.37 29,739.67 ii. Cash and cash equivalent 6,354.05 6,032.49 6,523.04 6,218.59 iii. Other bank balances 1,452.05 1,403.11 1,452.05 1,403.11 iv. Loans 42.59 66.14 42.59 66.14 Other current assets 10,522.30 10,100.85 10,533.73 10, 180,25 Current tax assets (net) 157.11 157.11 Total Current Assets 88,192.25 80,026.03 88,369.41 80,211.53 TOT AL ASSETS 1,45,048.48 1,34,158.84 1,45,117.23 1,34,237.40 EQUITY AND LIABILITIES Equity Equity share capital 1,002.83 1,002.83 1,006.84 1,002.83 Other equity 69,910.05 65,415.42 69,971.55 65,492.03 Equity attributable to owners of the parent 70,912.88 66,418.25 70,978.39 66,494.86 Non controlling interests 3.66 3.81 Total Equity 70,912.88 66,418.25 70,982.05 66,498.67 Liabilities Non.Current Liabilities Financial Liabilities i.Borrowings 9,226.38 10,503.55 9,226.38 10,503.55 ii. Other Financial Liabilities 555.36 555,36 555.36 555.36 iii.Lease liability 1,075.95 1,437.30 1,075.95 1,437.3 [Showing first 8,000 characters — download PDF for full document]